Adma Biologics (ADMA) FY2018 results: revenue $17 million, down 25.4% on the year
Adma Biologics, Inc. (ADMA) reported revenue of $17 million for fiscal 2018, the year ended 31 December 2018, down 25.4% on the year before. Net income was -$66 million, and diluted earnings per share $-1.45. The figures are the company's own, from the 10-K it filed with the SEC on 13 March 2019.
Revenue
$17 million
-25.4% on the year
FY2011FY2018
Operating margin
-354.9%
-172.7% a year earlier
FY2011FY2018
Net income
-$66 million
FY2011FY2018
Diluted EPS
-$1.45
FY2011FY2018
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Revenue
17.0
22.8
10.7
-25.4%
Cost of revenue
42.2
29.2
1.6
+44.7%
Gross profit
-25.2
-6.4
4.3
Gross margin
-148.4%
-28.1%
40.3%
Research and development
3.9
5.6
7.7
-29.5%
Operating income
-60.3
-39.3
-17.3
Operating margin
-354.9%
-172.7%
-162.6%
Interest expense
5.5
3.3
2.2
+68.1%
Pre-tax income
n/a
n/a
-19.5
Income tax
0.0
0.0
0.0
Net income
-65.7
-43.8
-19.5
Net margin
-387.1%
-192.3%
-183.1%
Diluted EPS
-$1.45
-$1.91
-$1.61
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Operating cash flow
-62.7
-37.3
-18.3
Capital expenditure
2.1
2.7
0.1
-21.7%
Free cash flow
-64.8
-39.9
-18.3
Free cash flow margin
-381.4%
-175.5%
-172.1%
Cash from investing
-2.1
15.2
0.9
Cash from financing
42.9
60.8
16.8
-29.3%
Depreciation and amortisation
2.6
1.5
0.4
+73.3%
Share-based compensation
2.2
1.6
1.3
+42.4%
Shares outstanding at period end
46m
37m
13m
+26.2%
Balance sheet
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Shareholders' equity
19.8
40.3
-4.5
-51.0%
Debt
44.1
43.0
20.2
+2.6%
Other liabilities
25.0
24.7
7.9
+1.3%
Total liabilities and equity
88.9
108
23.7
-17.7%
Fixed assets
30.1
30.5
2.0
-1.2%
Goodwill
3.5
3.5
0.0
0.0%
Intangible assets
4.0
4.8
0.0
-17.4%
Investments
n/a
0.0
5.4
Cash and equivalents
26.8
43.1
9.9
-37.9%
Receivables
1.4
3.9
1.0
-64.1%
Inventory
18.6
12.6
5.0
+47.4%
Other assets
4.5
9.6
0.3
-53.3%
Total assets
88.9
108
23.7
-17.7%
10-K for the year ended 31 December 2018, filed 13 March 2019: the filing.